RxDoctor Payments DataLook up a doctor →

Alkesh Patel, MD

Family Medicine · Columbia, MDNPI 1679505549

Payments from drug & device makers

$42,166in general payments, 2019–2025

Across 495 payments — averaging $85.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eisai Inc.$19K
  • AbbVie$13K
  • Novo Nordisk$2K
  • Amgen$960
  • Lilly USA, LLC$817
  • Amarin Pharma, Inc.$607
  • plus $6K from 38 others

What the payments were for

  • Consulting fees$5801%
  • Speaking & faculty fees$28,74868%
  • Travel & lodging$1,1443%
  • Food & beverage$11,68728%
  • Education$60%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$42,166 in reported general payments places this provider in the 95th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$187,229
Medicare patients
270
Services billed
2,323

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide46$53,680
EliquisApixaban37$49,232
JanuviaSitagliptin Phosphate24$35,489
JardianceEmpagliflozin21$33,701
FarxigaDapagliflozin Propanediol12$19,056
TrulicityDulaglutide14$14,491
Rosuvastatin Calcium173$3,753
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$3,531
Atorvastatin Calcium257$3,066
FenofibrateFenofibrate Nanocrystallized50$2,827
Losartan Potassium198$2,732
Levothyroxine Sodium195$2,094
Nebivolol Hcl24$2,024
Metformin Hcl175$1,938
Omega-3 Acid Ethyl Esters23$1,725

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,799$53,68046 claims
PfizerEliquis$447$49,23237 claims
MerckJanuvia$458$35,48924 claims
Boehringer IngelheimJardiance$288$33,70121 claims
AstraZenecaFarxiga$252$19,05612 claims
Lilly USA, LLCTrulicity$817$14,49114 claims
AbbVieSynthroid$12,592$1,30719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Columbia

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →